Head and neck squamous cell carcinoma (HNSCC) remains a globally prevalent malignancy with high morbidity and mortality. Despite therapeutic advances, patient outcomes are hindered by tumor ...
In a groundbreaking study published in Current Molecular Pharmacology, researchers have identified a novel biomarker for predicting prognosis and immunotherapy response in head and neck squamous cell ...
PDS Biotechnology is hosting a virtual key opinion leader event featuring notable experts in the field, which could enhance the company’s credibility and visibility in the oncological community. The ...
Bicara Therapeutics has released updated interim findings from its ongoing Phase I/Ib clinical trial of ficerafusp alfa for treating human papillomavirus (HPV)-negative recurrent/metastatic (R/M) head ...
Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects the mucous membranes of the mouth, nose, and throat. HNSCC is typically associated with tobacco exposure, alcohol abuse, ...
Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab to standard chemoradiotherapy significantly improved DFS for locoregional HNSCC. The ...
Keytruda's sBLA for LA-HNSCC treatment is under FDA priority review, with a decision expected by June 23. The KEYNOTE-689 trial showed significant improvements in event-free survival and major ...
The number of diagnosed incident cases of head and neck squamous cell carcinoma (HNSCC) are projected to climb from 229,000 cases in 2024 to 273,000 cases in 2034 across the eight major markets (8MM: ...
BASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results